Danish Zealand Pharma is recruiting for a Phase 2 study of its drug candidate, Petrelintide, a potential competitor to the best-selling Ozempic.
Share this post
Ozempic Challenger Advances
Share this post
Danish Zealand Pharma is recruiting for a Phase 2 study of its drug candidate, Petrelintide, a potential competitor to the best-selling Ozempic.